索磷布韦方案治疗维持性血液透析患者的丙型肝炎
本研究回顾性纳入印度62例未接受过治疗的维持性血液透析合并丙肝患者,采用索磷布韦为基础的方案治疗12周。结果显示95.2%患者获得持续病毒学应答,基因型不影响应答,37%出现并发症但无人因并发症停药。
要点
- 索磷布韦为基础方案在透析患者中SVR率达95.2%
- 基因型不影响持续病毒学应答
- 37%出现并发症,主要为消化不良和感染,无人停药
核心结论
- 索磷布韦为基础的直接抗病毒药物治疗在维持性血液透析患者中耐受良好且有效。
研究设计与样本
- 回顾性研究纳入62例未接受过治疗的维持性血液透析合并丙肝患者,均接受索磷布韦为基础方案治疗12周。
主要发现
- 23例(37%)出现并发症,其中13例(20.3%)消化不良,4例结核,3例细菌性肺炎。
- 利巴韦林组中23例(56%)需要增加促红细胞生成素剂量,无人因并发症停药。
关键数值与推荐
- 索磷布韦400mg每日或隔日,利巴韦林200mg每日,达拉他韦60mg每日,不同组合方案。
- 治疗12周,停药后12周评估SVR。
临床怎么用
- 索磷布韦为基础方案可用于透析合并丙肝患者,需监测并发症及促红细胞生成素需求。
局限性
- 回顾性设计,样本量较小,单中心经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is paucity of data on sofosubvir (SOF)-based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India. METHODS: All patients on MHD and treated with SOF-based therapy were included in this study. Before starting treatment, viral load, genotype, liver fibroscan, and upper gastrointestinal endoscopy were performed in all patients. SOF 400 mg/d or on an alternate day, ribavirin 200 mg/d and daclatasvir 60 mg/d were used in different regimens. Hepatitis C virus RNA was assessed at day 10 and at 4 weeks, at end of therapy, and at 12 weeks after stopping therapy. RESULTS: A total of 62 treatment-naïve patients were included. Mean age was 33.3 ± 10.2 years; 66% were men. Median number of copies were 106/dl. None had clinical evidence of cirrhosis. The most common genotype was genotype 1 in 64.5% of cases, followed by genotype 3 in 29% of cases. Thirty-nine patients were treated with SOF every other day/ribavirin, 2 patients with SOF daily/ribavirin, 6 with SOF every other day/daclatasvir, and 15 patients with SOF daily/daclatasvir. All patients were treated for 12 weeks. Fifty-nine (95.2%) patients had a sustained viral response (SVR). There was no impact of genotype on SVR. Twenty-three patients (37%) had complications while on therapy; 13 (20.3%) had dyspepsia, 4 had tuberculosis, and 3 had bacterial pneumonia. Most of the patients (n = 23; 56%) in the ribavirin group required an increase in the erythropoietin dose. No patient discontinued therapy due to complications. DISCUSSION: SOF-based DAAs were well tolerated and efficacious in this cohort of patients on MHD.
引用
- Agarwal SK, Bagchi S, Yadav RK, et al. Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. Kidney Int Rep. 2017. PMID: 29270489. doi:10.1016/j.ekir.2017.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。